ResMedのCEOであるMichael Farrellは,2026年3月9日に1.25Mドルの株式を売却し,株式の減少にもかかわらず,同社は強い利益を報告したため,その株式を1.06%削減した. ResMed CEO Michael Farrell sold $1.25M in stock on March 9, 2026, reducing his stake by 1.06%, as the company reported strong earnings despite a stock dip.

CEO マイケル・ファレルは2026年3月9日にResMedの株式4,991株を約125万ドルで平均価格251.03ドルで売却し,その株式を1.06%削減した. CEO Michael Farrell sold 4,991 shares of ResMed stock on March 9, 2026, for about $1.25 million at an average price of $251.03, reducing his stake by 1.06%. SECに提出され,事前に計画された計画の一部であるこの売却は,バードが目標価格を下げ,市場情勢が悪化した中で,3月11日の株価の2.6%の低下と一致しました. The sale, filed with the SEC and part of a pre-arranged plan, coincided with a 2.6% drop in the stock price on March 11, amid a lowered price target from Baird and broader market sentiment. 減少にもかかわらず,ResMedは1月に強い収入を報告し,収入は1年度に11%増加し,株式総額当たり1億円超え,収入は11%上昇した. Despite the decline, ResMed reported strong earnings in January, with revenue up 11% year-over-year and earnings per share exceeding estimates. 同社は,睡眠・呼吸療法機器の確かな市場位置を維持し,35. 17億円の市場キャップを備え,長期的に前向きな成績を誇る. The company maintains a solid market position in sleep and respiratory therapy devices, with a market cap of $35.17 billion and a long-term positive performance trend.